Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer (original) (raw)
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma
Valérie Combaret
Cancer research, 1992
View PDFchevron_right
Tumour necrosis factor-α, interleukin-1β and interleukin-6 in patients with renal cell carcinoma
Christine Dosquet
European Journal of Cancer, 1994
View PDFchevron_right
Regulatory T cells, interleukin (IL)-6, IL-8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma
Serena Zanotta, Francesca Capone, L. Portella
BJU International, 2013
View PDFchevron_right
Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial
J. Stouthard
British journal of cancer, 1996
View PDFchevron_right
Prediction of response to combined immunotherapy with interferon-α and low-dose interleukin-2 in metastatic renal cell carcinoma: Expression patterns of potential molecular markers in radical nephrectomy specimens
Masato Fujisawa
International Journal of Urology, 2009
View PDFchevron_right
Interleukin-6 and C-Reactive Protein in Metastatic Renal Cell Carcinoma
Ozden Altundag
Journal of Clinical Oncology, 2005
View PDFchevron_right
Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
Leif Bostad
2018
View PDFchevron_right
Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma
Christine Ménétrier-caux
International Journal of Cancer, 1997
View PDFchevron_right
Adjuvant Treatment With Interleukin-2- and Interferon-Alpha2a-Based Chemoimmunotherapy in Renal Cell Carcinoma Post Tumour Nephrectomy: Results of a Prospectively Randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
J. Atzpodien
The Journal of Urology, 2006
View PDFchevron_right
Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
Giuseppe Fornarini
Frontiers in Oncology, 2021
View PDFchevron_right
Inflammatory response markers and survival prediction in patients with renal cell carcinoma
Börje Ljungberg
Scandinavian Journal of Urology
View PDFchevron_right
The Biological Context of C-Reactive Protein as a Prognostic Marker in Renal Cell Carcinoma: Studies on the Acute Phase Cytokine Profile
L. Bostad
Cancers
View PDFchevron_right
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie
David Perol
Annals of Oncology, 2002
View PDFchevron_right
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma
Thomas E Hutson
British Journal of Cancer, 2017
View PDFchevron_right
Correlation of Prognostic Inflammatory Markers with Renal Tumour Characteristics-A Prospective Study
SASANKA K U M A R BARUA
View PDFchevron_right
Prognostic histological and immune markers of renal cell carcinoma
László Kaizer
Pathology & Oncology Research, 2001
View PDFchevron_right
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
Giuseppe Fornarini
Journal of Translational Medicine
View PDFchevron_right
Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005)
Fairooz Kabbinavar, Allan Pantuck
Cancer, 2008
View PDFchevron_right
C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality
Paul Perrotte
Cancer, 2007
View PDFchevron_right
Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma
Allan Pantuck
Cancer, 2003
View PDFchevron_right
Evaluation of Role of Inflammatory Markers for the Prediction of Recurrence on Pathologic T1a Clear Cell Renal Cell Cancer Patients
Nurullah Hamidi
Üroonkoloji Bülteni, 2016
View PDFchevron_right
Prognostic biomarkers in renal cell carcinoma
Komathi Perumal
Expert Review of Molecular Diagnostics, 2007
View PDFchevron_right
A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2
Anne Soerensen, Frede Donskov
Acta oncologica (Stockholm, Sweden), 2015
View PDFchevron_right
Interleukin-6/10 Ratio as a Prognostic Marker of Recurrence in Patients With Intermediate Risk Urothelial Bladder Carcinoma
Galliano Tinacci
Journal of Urology, 2007
View PDFchevron_right
Prognostic significance of inflammatory markers in patients with rare kidney cancers
SASANKA K U M A R BARUA
International Surgery Journal
View PDFchevron_right
Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients. Commentary
Hirotsugu Uemura
European Urology, 2010
View PDFchevron_right
Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients
Hirotsugu Uemura
European Urology, 2010
View PDFchevron_right
Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma
Bruno Turlin
Urology, 2000
View PDFchevron_right
Intratumor C-Reactive Protein as a Biomarker of Prognosis in Localized Renal Cell Carcinoma
Sohail Abbasi
Journal of Urology, 2011
View PDFchevron_right
The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors
Özlem Sever
Scientific Reports
View PDFchevron_right
The Relationship Between Systemic Immune Inflammation Index and Treatment Response in Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors: Results from The Turkish Oncology Group Kidney Cancer Consortium Database
Orcun Can
2021
View PDFchevron_right
Interleukin-6 in renal disease and therapy
Ceri A Fielding
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2014
View PDFchevron_right
Long-term immunotherapy with low-dose interleukin-2 and interferon-? in the treatment of patients with advanced renal cell carcinoma
S. Andrulli
Cancer, 2001
View PDFchevron_right
Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis
Robert Harris
Oncoimmunology, 2016
View PDFchevron_right
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy
Luciano Burattini
Targeted Oncology, 2015
View PDFchevron_right